Emerging therapies for small cell lung cancer

Currently, chemotherapy remains the standard treatment for first- and second-line management of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of SCLC, and nivolumab, pembrolizumab, atezolizumab, and durvalumab have led to significant improvements in clinical outcomes of SCLC. Regarding options in other classes of therapy, the cytotoxic drug lurbinectedin was granted orphan drug status based on a remarkable objective response rate of 39.3%. In addition, an increase in progression-free survival (PFS) was achieved in a phase II study of anlotinib (ALTER 1202). Future prospects for even better outcomes in SCLC lie in novel ways to integrate immunotherapy and small-molecule TKI…

• EU
  Emory University
• NN
  National Natural Science Foundation of China

  Awards: 81272600, No. 81272600
• WJ
  Wu Jieping Medical Foundation
• SO
  School of Medicine, Emory University
• WC
  Winship Cancer Institute
• SA
  Science and Technology Innovation Talents in Universities of Henan Province